Clinical Outcome of Multicatheter Brachytherapy APBI in breast-conserving Therapy (COMBAT) for breast cancer patients after neoadjuvant chemotherapy

Clinical Outcome of Multicatheter Brachytherapy APBI in breast-conserving Therapy (COMBAT) for breast cancer patients after neoadjuvant chemotherapy - COMBAT-NEO

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026976

Enrollment

Registered

2017-04-13

Start date

2017-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Breast-conserving therapy using multicatheter brachytherapy APBI(4Gyx8fr)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed breast cancer 2. Stage I~III 3. Maximum diameter is 3cm or less after chemotherapy 4. Candidate of breast-conserving surgery 5. Female 6. Age is 40 years or older 7. Written informed consent form

Exclusion criteria

Exclusion criteria: 1. Mastectomy 2. Recurrent disease 3. Paget disease 4. Connective tissue disease 5. Pregnancy 6. Inappropriate cases judged by investigators

Design outcomes

Primary

Measure	Time frame
Acute toxicities	—

Secondary

Measure	Time frame
1. long-term cosmesis at 5 years after PBI 2. locoregional and distant recurrences 3. long-term side effectsat 3 months to 5 years after PBI, severities, grades 4. cancer-specific death and other causes	—

Countries

Japan

Contacts

Public ContactHiromi Fuchikami

Tokyo-West Tokushukai Hospital Department of Breast Oncology

sswkw540@gmail.com+81-570-064-660

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026